{"id":565832,"date":"2026-09-28T00:30:00","date_gmt":"2026-09-27T22:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=565832"},"modified":"2026-09-26T23:09:45","modified_gmt":"2026-09-26T21:09:45","slug":"la-dapagliflozine-un-inhibiteur-du-sglt-2-en-traitement-dappoint-a-un-inhibiteur-du-sra","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/la-dapagliflozine-un-inhibiteur-du-sglt-2-en-traitement-dappoint-a-un-inhibiteur-du-sra\/","title":{"rendered":"La dapagliflozine, un inhibiteur du SGLT-2, en traitement d&#8217;appoint \u00e0 un inhibiteur du SRA"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Le large \u00e9ventail d&#8217;effets th\u00e9rapeutiques des inhibiteurs du SGLT-2 (cotransporteurs sodium-glucose de type 2) comprend notamment la protection cardior\u00e9nale chez les patients atteints d\u2019insuffisance r\u00e9nale chronique (IRC) non diab\u00e9tique, comme le d\u00e9montrent de mani\u00e8re impressionnante de grands essais cliniques randomis\u00e9s contr\u00f4l\u00e9s (ECR) men\u00e9s chez des adultes (par exemple DAPA-CKD, EMPA-KIDNEY) le d\u00e9montrent de mani\u00e8re convaincante. Entre-temps, une \u00e9tude de phase III intitul\u00e9e DOUBLE PROTECT Alport (NCT05944016) a \u00e9t\u00e9 lanc\u00e9e, dans laquelle l\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 des inhibiteurs du SGLT2 en compl\u00e9ment du traitement standard sont \u00e9valu\u00e9es chez des patients \u00e2g\u00e9s de 10 \u00e0 40 ans atteints d\u2019une insuffisance r\u00e9nale chronique d\u2019origine g\u00e9n\u00e9tique (syndrome d\u2019Alport).<\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fla-dapagliflozine-un-inhibiteur-du-sglt-2-en-traitement-dappoint-a-un-inhibiteur-du-sra%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Le large \u00e9ventail d&#8217;effets th\u00e9rapeutiques des inhibiteurs du SGLT-2 (cotransporteurs sodium-glucose de type 2) comprend notamment la protection cardior\u00e9nale chez les patients atteints d\u2019insuffisance r\u00e9nale chronique (IRC) non diab\u00e9tique, comme&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fla-dapagliflozine-un-inhibiteur-du-sglt-2-en-traitement-dappoint-a-un-inhibiteur-du-sra%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":565833,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Maladie r\u00e9nale d'origine g\u00e9n\u00e9tique : DOUBLE PROTECT Alport","footnotes":"[{\"content\":\"<em>d\\u00e9bit de filtration glom\\u00e9rulaire estim\\u00e9 (DFGe) > 60 ml\\\/min\\\/1,73 m\\u00b2 ;<\\\/em>\",\"id\":\"de281f80-e833-44d8-8f97-4476b5bc7e6c\"},{\"content\":\"<em>En ce qui concerne la canagliflozine, qui est \\u00e9galement un inhibiteur du SGLT-2, l'autorisation de Swissmedic se limite actuellement \\u00e0 la n\\u00e9phropathie diab\\u00e9tique chez l'adulte (informations \\u00e0 la date du 03\\\/09\\\/2026).<\\\/em>\",\"id\":\"6d28f7e2-6362-4781-bb54-2555ce6ea639\"}]","_members_access_role":[],"_members_access_error":""},"category":[11549,11527,11531,11417,11315,11434],"tags":[23505,100907,12826,66548,23395,100905,24198,100906,21442,100908,71829,100909],"powerkit_post_featured":[],"class_list":["post-565832","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-etudes","category-formation-continue","category-genetique","category-medecine-interne-generale","category-nephrologie-fr","tag-add-on-fr","tag-blocage-du-systeme-ras","tag-ckd-fr","tag-dapa-ckd-fr","tag-dapagliflozine","tag-double-protect-alport","tag-inhibiteur-de-sglt-2","tag-insuffisance-renale-chronique-dorigine-genetique","tag-maladie-renale","tag-nct05944016","tag-protection-cardiorespiratoire","tag-traitement-dappoint","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-05 02:35:01","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":565836,"slug":"linibitore-sglt-2-dapagliflozina-come-terapia-aggiuntiva-alla-terapia-con-inibitori-del-sistema-renina-angiotensina-ras","post_title":"L'inibitore SGLT-2 dapagliflozina come terapia aggiuntiva alla terapia con inibitori del sistema renina-angiotensina (RAS)","href":"https:\/\/medizinonline.com\/it\/linibitore-sglt-2-dapagliflozina-come-terapia-aggiuntiva-alla-terapia-con-inibitori-del-sistema-renina-angiotensina-ras\/"},"pt_PT":{"locale":"pt_PT","id":565842,"slug":"o-inibidor-da-sglt-2-dapagliflozina-como-tratamento-complementar-a-inibicao-do-sra","post_title":"O inibidor da SGLT-2 dapagliflozina como tratamento complementar \u00e0 inibi\u00e7\u00e3o do SRA","href":"https:\/\/medizinonline.com\/pt-pt\/o-inibidor-da-sglt-2-dapagliflozina-como-tratamento-complementar-a-inibicao-do-sra\/"},"es_ES":{"locale":"es_ES","id":565847,"slug":"la-dapagliflozina-un-inhibidor-de-la-sglt-2-como-tratamiento-complementario-al-bloqueo-del-sra","post_title":"La dapagliflozina, un inhibidor de la SGLT-2, como tratamiento complementario al bloqueo del SRA","href":"https:\/\/medizinonline.com\/es\/la-dapagliflozina-un-inhibidor-de-la-sglt-2-como-tratamiento-complementario-al-bloqueo-del-sra\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/565832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=565832"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/565832\/revisions"}],"predecessor-version":[{"id":568600,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/565832\/revisions\/568600"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/565833"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=565832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=565832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=565832"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=565832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}